Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
AI and Machine Learning
Merck grows more ambitious about 'workhorse' TROP2 ADC
Merck has already registered 15 global phase 3 trials for its Kelun-partnered TROP2 antibody-drug conjugate, sac-TMT.
Angus Liuu
Oct 20, 2025 4:00pm
ESMO: Datroway data edge out Trodelvy in first TROP2 face-off
Oct 19, 2025 2:30am
ESMO: Enhertu wields 2-fisted power in early breast cancer
Oct 18, 2025 10:30am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am
TROP2 showdown, InnoCare-Zenas, Lupin—Fierce Pharma Asia
Oct 10, 2025 10:55am
AZ, Daiichi's Enhertu notches another win in early breast cancer
Sep 29, 2025 12:00pm
